Director sold ~$358K of Halozyme
Scheduled in advanceLoading…
Halozyme
HALO · NASDAQ · Biotechnology
HALO · NASDAQ · Biotechnology
Biotechnology company based in San Diego, California.
In the last 90 days, no insider of Halozyme reported an open-market purchase and 29 open-market sales worth about $15.6M. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$108.31
Last 12 months
Not enough history
Market value
$12.3B
Revenue
$481M
+47.7% vs the same quarter a year earlier
Free cash flow, last 12 months
$806M
This quarter $237M, a year earlier $98.1M
Net debt
$1.98B
Debt $2.15B, cash $163M, at Jun 30, 2026
Net income, last 12 months
$414M
Operating profit covers interest 29.4x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 6, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
29 sales
$15.6M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$1.4B
+37.6% vs the year before
Net income, fiscal 2025
$317M
As reported in the annual filing
Shares outstanding
113M
As of Jul 31, 2026
In fiscal 2025 the company spent $342M buying back its own shares. Cash actually paid, from its cash-flow statement.
Director sold ~$358K of Halozyme
Scheduled in advanceDirector sold ~$121K of Halozyme
Scheduled in advanceDirector sold ~$78K of Halozyme
Scheduled in advanceDirector sold ~$961K of Halozyme
Scheduled in advancePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last 12 months, adjusted daily closes
Adjusted close went from $66.97 on Oct 6, 2025 to $108.31 on Oct 5, 2026 (+61.7%). Disclosed activity in the last 12 months: 0 insider purchases, 94 insider sales (91 under pre-arranged plans), 0 Congress purchases, 0 Congress sales.
1 active phase 3 trial and 0 active phase 2 trials led by this company, mostly in hypogonadism, male. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Top officer leaving
“Ramsay continues to serve as Interim CFO on July 1, 2026, he will be granted an additional 2,500 RSUs which will vest on his employment termination date and be subject to a one-year holding period from the vesting date.”
2 insiders sold ~$9.28M in the 60 days before
8-K on sec.govTop officer leaving
“(“the Company”) announced a transition plan in which Nicole LaBrosse, Senior Vice President, Chief Financial Officer will continue to serve as the Company’s Chief Financial Officer until the earliest of when a new chief financial officer is hired, March 30, 2026 or such earlier date determined by the Company (the “Separation Date”) and then depart to pursue a new professional opportunity.”
3 insiders sold ~$4.58M in the 60 days before
8-K on sec.govTop officer leaving
“The Company announced today a transition plan in which Nicole LaBrosse, Senior Vice President and Chief Financial Officer (“CFO”) will continue to serve as the Company’s CFO until the earlier of when a new chief financial officer is hired, or until March 30, 2026 (the “Separation Date”) and then depart to pursue a new professional opportunity.”
1 insider sold ~$278K in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.